Lazaros I Sakkas
University of Thessaly, Greece
Title: ANA-specific antigen recognition in patients with psoriatic arthritis and psoriasis
Biography
Biography: Lazaros I Sakkas
Abstract
Introduction: Antinuclear antibodies (ANAs) may be detected in psoriatic arthritis (PsA) and psoriasis (Ps) but the antigen-specificities have not been defined. International Consensus on ANA patterns (ICAP) has reported 14 ANA immunofluorescence (IF) patterns and commercial molecular-based multiplex assays were developed to assist ICAP’s IF ANA testing.
Aim: To identify ANA specificities in Ps and PsA using a recently developed multiplex immunoassay specifically designed for ANA.
Material & Methods: A total of 70 patients (38 female) with Ps (n=36) or PsA (n=34) and 50 demographically matched normal controls (NCs) were tested by an ANA line immunoassay containing 23 different antigens: dsDNA, nucleosomes, histones, SS-A, Ro-52, SS-B, nRNP/Sm, Sm, Mi-2α, Mi-2β, Ku, CENP A, CENP B, Sp100, PML, Scl-70, PM-Scl100, PM-Scl75, RP11, RP155, gp210, PCNA and DFS70.
Results: Overall, reactivity to at least 1 against antigen was found in 23/70 patients (32.9%) compared to 6/50 (12%) NCs (p=NS; Ps vs PsA, p=NS). Specifically, the ICAP-related abs in Ps/PsA patients were as follows: AC-1:4.3%; AC-2:10%; AC-3:0.7%; AC-4:11.4%; AC-5:0.7%; AC-6:0.7%; AC-8:2.8%, and AC-10: 2.1%, while in NCs ICAP-related abs were as follows: AC-2:4%; AC-4:4%, AC-3:2%; AC-8:2% and AC-11:2% pattern. There was no statistically difference for the presence of ICAP between Ps and PsA and between Ps/PsA and NCs.
Conclusion: Testing for ANA specificities does not reveal a dominant ANA target in PsA and Ps.